Drugs / MSGV1-PSCA-8T28Z
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06193486 | Oct 2024 → Jan 2029 expected | castration-resistant prostate carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSGV1-PSCA-8T28Z | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06193486 ↗ |
| Modality | Cell therapy | “Autologous Gamma Delta T Cells” NCT06193486 ↗ |
| Target | PSCA | “Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.” NCT06193486 ↗ |